Vitamin D metabolism in osteogenesis imperfecta during calcitonin therapy.
The effect of calcitonin on plasma concentrations of 25-hydroxyvitamin D (25-OHD) and 1,25-dihydroxyvitamin D [1,25-(OH)2D] was studied in six patients with osteogenesis imperfecta. The mean pretreatment value of plasma 1,25-(OH)2D was significantly higher than the mean value of age-matched control subjects (P less than .05). High or normal plasma levels of 1,25-(OH)2D before calcitonin therapy were decreased after 1 month of therapy and remained normal thereafter in all six patients. Plasma 25-hydroxyvitamin D concentrations, which were normal before calcitonin injection, remained normal during calcitonin administration. These results indicate that there may be acute and chronic effects of calcitonin on vitamin D metabolism.
D000293:Adolescent; D000469:Alkaline Phosphatase / Q000097:blood; D002116:Calcitonin / Q000494:pharmacology / Q000627:therapeutic use*; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000652:urine; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007223:Infant; D008297:Male; D010013:Osteogenesis Imperfecta / Q000188:drug therapy* / Q000378:metabolism; D010758:Phosphorus / Q000652:urine; D014807:Vitamin D / Q000097:blood / Q000378:metabolism*
D014807:Vitamin D; D010758:Phosphorus; D002116:Calcitonin; D000469:Alkaline Phosphatase; D002117:Calcitriol; D006909:Hydroxyproline; D002118:Calcium